(DNLI) Denali Therapeutics - Overview
Stock: RIPK1 Inhibitor, eIF2B Activator, LRRK2 Inhibitor, ETV Therapy, OTV Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 64.8% |
| Relative Tail Risk | -9.59% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.14 |
| Alpha | -30.27 |
| Character TTM | |
|---|---|
| Beta | 1.345 |
| Beta Downside | 1.245 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.20% |
| CAGR/Max DD | -0.16 |
Description: DNLI Denali Therapeutics January 14, 2026
Denali Therapeutics (NASDAQ: DNLI) is a U.S. biotech focused on discovering and developing disease-modifying therapies for neurodegenerative and lysosomal storage disorders, leveraging its proprietary enzyme transport vehicle (TV) and omnipotent delivery (OTV) platforms.
The pipeline spans multiple modalities: a RIPK1 inhibitor (Eclitasertib) for peripheral inflammation; an eIF2B activator (DNL343) for ALS; LRRK2 inhibitor (BIIB122/DNL151) for Parkinson’s; frontotemporal dementia-granulin therapy (TAK-594/DNL593); enzyme-replacement candidates for Sanfilippo A (DNL126) and Hunter syndrome (DNL310); TV-based programs for Pompe disease (DNL952), Gaucher/Parkinson’s (DNL111), and Hurler syndrome (DNL622); and OTV/antibody TV candidates targeting tau, α-synuclein, and Aβ in Alzheimer’s and Parkinson’s disease.
As of the latest 10-Q (Q3 2024), Denali reported ~ $320 million in cash and equivalents, a burn rate of roughly $150 million per year, and a market-cap of ~ $2.1 billion-metrics that suggest a runway of just over two years without additional financing. The company’s valuation is heavily influenced by the broader biotech sector’s 2023-24 surge in CNS-focused R&D funding (CAGR ≈ 12 %) and by its strategic partnership with Biogen on the LRRK2 program, which could de-risk later-stage development. For a deeper, data-driven view of DNLI’s risk-adjusted upside, you may find it useful to explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA -13.08 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.38 > 3% & CFO -397.8m > Net Income -498.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.4m) vs 12m ago 1.75% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 22.73%; Δ -22.73% > 0%) |
| Interest Coverage Ratio: -11.15 > 6 (EBITDA TTM -534.2m / Interest Expense TTM -49.1m) |
Altman Z'' -15.00
| A: 0.75 (Total Current Assets 882.6m - Total Current Liabilities 90.1m) / Total Assets 1.06b |
| B: -1.82 (Retained Earnings -1.92b / Total Assets 1.06b) |
| C: -0.44 (EBIT TTM -547.8m / Avg Total Assets 1.25b) |
| D: -14.84 (Book Value of Equity -1.92b / Total Liabilities 129.4m) |
| Altman-Z'' Score: -19.53 = D |
What is the price of DNLI shares?
Over the past week, the price has changed by -3.04%, over one month by +22.49%, over three months by +46.29% and over the past year by -6.44%.
Is DNLI a buy, sell or hold?
- StrongBuy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DNLI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.9 | 55.9% |
| Analysts Target Price | 32.9 | 55.9% |
| ValueRay Target Price | 21.8 | 3.3% |
DNLI Fundamental Data Overview February 03, 2026
P/B = 3.6705
Revenue TTM = 0.0 USD
EBIT TTM = -547.8m USD
EBITDA TTM = -534.2m USD
Long Term Debt = 44.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.16m USD (from shortTermDebt, last quarter)
Debt = 44.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -46.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.59b USD (3.39b + Debt 44.4m - CCE 848.2m)
Interest Coverage Ratio = -11.15 (Ebit TTM -547.8m / Interest Expense TTM -49.1m)
EV/FCF = -6.31x (Enterprise Value 2.59b / FCF TTM -410.8m)
FCF Yield = -15.86% (FCF TTM -410.8m / Enterprise Value 2.59b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 105.0m) / Revenue TTM)
Tobins Q-Ratio = 2.45 (Enterprise Value 2.59b / Total Assets 1.06b)
Interest Expense / Debt = 47.48% (Interest Expense 21.1m / Debt 44.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -432.8m (EBIT -547.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.79 (Total Current Assets 882.6m / Total Current Liabilities 90.1m)
Debt / Equity = 0.05 (Debt 44.4m / totalStockholderEquity, last quarter 926.2m)
Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -46.6m / EBITDA -534.2m)
Debt / FCF = 0.11 (negative FCF - burning cash) (Net Debt -46.6m / FCF TTM -410.8m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -39.75% (Net Income -498.7m / Total Assets 1.06b)
RoE = -46.33% (Net Income TTM -498.7m / Total Stockholder Equity 1.08b)
RoCE = -48.88% (EBIT -547.8m / Capital Employed (Equity 1.08b + L.T.Debt 44.4m))
RoIC = -40.21% (negative operating profit) (NOPAT -432.8m / Invested Capital 1.08b)
WACC = 11.21% (E(3.39b)/V(3.44b) * Re(10.87%) + D(44.4m)/V(3.44b) * Rd(47.48%) * (1-Tc(0.21)))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.68%
Fair Price DCF = unknown (Cash Flow -410.8m)
EPS Correlation: -2.55 | EPS CAGR: 25.09% | SUE: 4.0 | # QB: 1
Revenue Correlation: -57.19 | Revenue CAGR: -1.07% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.76 | Chg30d=+0.013 | Revisions Net=+1 | Analysts=6
EPS next Year (2026-12-31): EPS=-2.94 | Chg30d=+0.034 | Revisions Net=+1 | Growth EPS=+2.3% | Growth Revenue=+2252.3%